Suggestions
Jason C. Foster
Not afraid of doing hard things
Jason C. Foster is a seasoned professional with a strong background in the healthcare industry, focusing on optimizing organizational value and achieving returns for investors through product and service enhancement.
His academic journey includes a Master of Business Administration from Columbia Business School, a BA in Government from the University of Virginia, and high school education in Richmond, Virginia at Collegiate School.
Jason has held various key positions in renowned organizations such as Altius bioventures, THENA Capital, Credentially, Ataraxia Partners, Ori Biotech, GripAble, Auxita, Deep Science Ventures, Health Equity Consulting Ltd, hystrix medical AG, Salve, Techstars, Indivior, and Reckitt Benckiser Pharmaceuticals, among others.
His roles have ranged from Investment Committee member to Chief Executive Officer, Strategic Advisor, Managing Director, Marketing Director, Brand Manager, and more, showcasing a diverse skill set and extensive experience in the industry.
Furthermore, Jason has also served in leadership positions at reputable companies like Medco Health Solutions, USADemocracy.com, and U.S. House of Representatives, Commerce Committee, demonstrating a well-rounded professional background across different sectors.
With a focus on the UK, US, and EU healthcare markets, Jason leverages his expertise to help organizations amplify the value of their offerings, ultimately contributing to enhanced health outcomes and lucrative returns for stakeholders.
Highlights
We have updated the Ori Biotech patient tracker on our website (link below) based on the Q2 revenue numbers reported by the commercial cell therapy manufacturers. Some highlights:
- Amtegvi® looks to have treated about 25 patients in its first quarter of launch
- Kymriah® and Yescarta® volumes looking on track to be flat in 2024 at ~1000 and ~4000 patients treated respectively. Kymriah has been roughly flat since 2020.
- Tecartus® looks on track for about a 10% increase in patients treated while Abecma® looks to be on track for a 25% decrease in number of patients treated -- likely due to previously disclosed manufacturing challenges
- The big gainers are Breyanzi® (+43%) and Carvykti® (+37%) likely due to approval for 2nd line treatment for both
- In total, all cell therapy products are on track to treat >10K patients in a year for the first time
- Next update it will interesting to see the continued trends and to see the first data from Tecelra® which is currently being launched by Adaptimmune (Q3 '24 numbers available in Nov 2024)
#celltherapy #cellandgenetherapy #biotechnology #manufacturingbrighterfuturestogether
Disclaimer: These numbers are inferred from publicly reported revenue numbers and therefore are directionally correct but likely specifically wrong. They wouldn't account for patients previously treated in clinical trials or those treated on compassionate use who were not charged.
Unfortunately, patient access to the approved cell therapies continues to be a challenge globally. As an industry, we need to ensure we are continuing to develop therapies that are not only approvable but also affordable and accessible. I can't wait for Ori Biotech's partners to begin clinical trials using the IRO platform, scheduled for 2025, and to start demonstrating the safety, efficacy AND commercial viability of their products!
#celltherapy #cellandgenetherapy #biotechnology #manufacturingbrighterfutures
